Sunshield Chemicals Ltd Q3 FY26 – ₹95 Cr Quarterly Revenue, 200% PAT Jump, ₹130 Cr Rights Issue Hangover & a Valuation That’s Trying to Look Premium
1. At a Glance – Blink and You’ll Miss the Plot
If there were a reality show called “Smallcap Chemicals: Growth, Guts & Gearing”, Sunshield Chemicals Ltd would be the contestant quietly sitting in the corner, occasionally dropping a 200% profit growth bomb and then going back to work like nothing happened.
Market cap sits at ₹729 crore, current price around ₹829, down ~21% in the last three months because markets apparently don’t like rights issues even when they’re needed. FY25 sales clocked ₹442 crore, Q3 FY26 revenue came in at ₹95 crore, and PAT for the quarter jumped 200% YoY to ₹4.89 crore. ROE is a respectable 16.4%, ROCE 14.9%, and debt-to-equity stands at 0.81—not scary, but not monk-like either.
The company raised ₹129.9 crore via a rights issue at ₹901 in Oct 2025, which explains both the balance sheet muscle-building and the stock’s recent sulking. Specialty chemicals, niche products, steady clients, expanding capacity—yet the market treats it like a mid-term exam answer written too neatly: “Good, but not exciting.” Or is it?
Before you scroll away, ask yourself: how many sub-₹1,000 crore specialty chemical companies do you know that supply Lubrizol, Solvay, Asian Paints, and Godrej? Exactly. Now let’s get into the masala.
2. Introduction – A Chemical Company That Hates the Limelight
Sunshield Chemicals is not a flashy capex-announcing, LinkedIn-posting, “China+1 will make us trillionaires” kind of company. It is the quiet chemistry topper who keeps getting decent marks, sometimes flunks (hello 2016–17), then suddenly turns into a ranker post-2020.
Incorporated in 1986, Sunshield operates squarely in specialty chemicals, not commodities. That means smaller volumes, higher value-add, sticky customers, and customers who hate switching suppliers because one wrong molecule can ruin their entire formulation. From PVC stabilizers to antioxidants, from ethoxylates to niche polyurethane chain extenders—Sunshield is basically the guy who supplies ingredients, not the final Maggi packet.
The last five years have been transformative. Sales CAGR of 15%, profit CAGR of 65%, and ROE consistently above 20% until FY24. Then came capex, modernization, debottlenecking, and finally the big daddy—the rights issue. Markets panicked, price corrected, and here we are.
So the question isn’t “Is Sunshield good?” The real question is: Is Sunshield done digesting its expansion, or is the chemistry just beginning to react?
3. Business Model – WTF Do They Even Do?
Let’s simplify before your brain smells like ethylene oxide.
Sunshield manufactures specialty chemicals used as inputs across multiple industries:
Home & Personal Care
Paints & Coatings
Agrochemicals
Lubricants
Plastics, Polymers & Rubber
Key Products (Translated from Chemical to Human)
THEIC – Heat & PVC stabilizer → Prevents plastics from behaving like melted cheese in summer.
Ethoxylates & Propoxylates → Used everywhere: detergents, agrochemicals, paper, dyes. Basically the Swiss Army knife of chemicals.
Antioxidants → Stop plastics, rubber, fuels from aging badly. Anti-wrinkle cream for polymers.
HQEE → A niche polyurethane chain extender. Very few players, very sticky customers.
BC 700 → Paints & varnish additive for texture and finish. The “Instagram filter” of coatings.
This is B2B chemistry, not bulk acid manufacturing. Customer qualification cycles are long, approvals painful, but once in—you’re family.
Ask yourself: how often does Asian Paints change chemical suppliers just to save 2%? Exactly.
4. Financials Overview – Numbers Don’t Lie, They Just Smirk
Quarterly Performance (Q3 FY26 – Figures in ₹ Crore)
Metric
Latest Qtr (Dec’25)
YoY Qtr (Dec’24)
Prev Qtr (Sep’25)
YoY %
QoQ %
Revenue
94.96
84.61
122.40
12.2%
-22.4%
EBITDA
9.08
6.79
14.02
33.7%
-35.2%
PAT
4.89
1.63
7.23
200%
-32.4%
EPS (₹)
5.56
1.85
8.22
200%
-32.4%
Annualised EPS (Q3 rule): Average of Q1, Q2, Q3 × 4 Q1 EPS: 6.52 | Q2 EPS: 7.75 | Q3 EPS: 5.56 Average = 6.61 → Annualised EPS ≈ ₹26.4
At CMP ₹829, P/E ≈ 31.4x (not cheap, not absurd).
Yes, QoQ dipped—because Q2 was unusually strong. But YoY? Chef’s kiss.
So tell me: would you rather own a company with volatile growth or one with boring decline?
5. Valuation Discussion – Not Cheap, Not Delusional
Method 1: P/E Band
Normalized EPS: ₹26–28
Reasonable multiple for niche specialty chem: 22x–28x
